Introduction & Objective: Screening for preclinical T1D and early-stage monitoring are typically only accessible in research studies, but will likely soon expand to clinical settings. Potential strategies for conducting monitoring of early-stage T1D in clinical settings must be explored. This study assessed feasibility of remote SMBG in youth with preclinical T1D.
Methods: Participants from the Autoimmunity Screening for Kids (ASK) study were eligible if enrolled in ASK ≥6 months prior to this study’s start. Upon enrollment in the SMBG study, participants transitioned to an advanced technology glucometer (OneTouch Verio Reflect®) with remote data sharing capability. 12 months of remotely transferred SMBG data was collapsed into 3-month sums and SMBG frequency was explored with Poisson regression.
Results: Data from 42 participants were included (age 13 ± 4.1 years, 62% non-Hispanic white, 62% female, 17% T1D first-degree relative). Frequency of SMBG was highest in the first 3 months (median [IQR]: 3.0 [1.0-8.5]). SMBG frequency decreased over time; there were fewer SMBG in months 4-6 (1.0 [0.0-4.3]), 7-9 (0.0 [0.0-2.3]), and 10-12 (0.0 [0.0-2.0]) (p<0.0001).
Conclusion: Use of devices with remote data transfer is one potential tactic to support clinicians in conducting early-stage T1D monitoring. Strategies to sustain engagement are needed; qualitative studies may provide insight into barriers.
M.E. Pauley: None. C. Geno Rasmussen: None. K.A. Bautista: None. M. Munoz: None. I. Taki: None. F. Sepulveda: None. J. Baxter: None. M. Rewers: Advisory Panel; Sanofi. Other Relationship; Sanofi. Consultant; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Consultant; Provention Bio, Inc. Research Support; Hemsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases. K.M. Simmons: Advisory Panel; Provention Bio, Inc. Consultant; Provention Bio, Inc. Research Support; Provention Bio, Inc., Novartis AG. Consultant; Medtronic.
JDRF (2-SRA-2022-1270-S-B); NIH NIDDK (T325T32DK063687); DiabDocs Physician-Scientist Career Development Award: NIH NIDDK (K12DK133995) & The Leona M. and Harry B. Helmsley Charitable Trust to Stanford University (2305-06041)
